10x Genomics, Inc.
In the published model solve dated 2026-Q2, anchored at $47.48, 10x Genomics, Inc. (TXG) is priced for today's economics sustained for ~20.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• 10x Genomics sells single-cell and spatial-biology instruments plus the consumables that run on them, a razor-and-blade model for academic and biopharma labs, but its core is shrinking: the 10-K discloses single-cell solutions revenue fell from $407.5 million in 2024 to $385.9 million in 2025 (accession 0001628280-26-007822). • The dominant risk is customer funding, which the company cannot control: the filing notes that in March 2025 the NIH terminated approximately 700 research grants totali
Is TXG overvalued? See what's priced in →
319 institutional managers reported holding TXG in 13F filings for the quarter ended 2026-03-31. 47 opened new positions that quarter. Held by FMR (Fidelity), Vanguard Group, ARK Investment Management, among others. On the short side, 22.1M shares were sold short as of the 2026-06-15 count, about 17% of shares outstanding (6.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TXG's share count grew 16.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TXG over the trailing three years: 2025: 1 buy totaling $446k. 10 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TXG's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -4.5% | -31.0% |
| 2023-11-04 | +15.7% | +30.0% |
| 2024-02-16 | +0.8% | -42.3% |
| 2024-05-01 | -5.2% | -30.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TXG's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-06-08 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-02-12 (items 2.02, 9.01); 2026-01-12 (items 2.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.